CYP2C19 and stroke disorder: Our study mainly investigated the effect of CYP2C19 polymorphism on PD (high platelet reactivity or platelet reactivity level) and clinical outcomes (MACEs, MI, revascularization, stroke, definite stent thrombosis, and bleeding) for patients treated with ticagrelor.